Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Imunon Inc

IMNN ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.19

▲ +17.82%

Market Cap $6.68M · Vol 40.08K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.68M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+65.96%

YoY

RSI (14)

39.84

Momentum

Beta

2.05

vs Market

52W High

$5.10

80.43% below

52W Low

$0.96

5.21% above

Volume

40.08K

Avg 21.43K

P/B

1.84

Price-to-book

ROE

N/A

Return on equity

Free Float

93.73%

Public shares

Shariah Compliance8 STANDARDS

✗ Imunon Inc (IMNN) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IMNN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+14.42%

-16.78%

-28.74%

-60.60%

YTD

-68.77%

-76.46%

-90.33%

-99.37%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-14,495,030.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-131.74% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.84
P/FCF	N/A
EPS Growth	+65.96%
Outstanding Shares	5.61M

Technical Indicators

50-Day SMA	$1.39
200-Day SMA	$2.33
RSI (14)	39.84
Beta	2.05
52-Week High	$5.10
52-Week Low	$0.96

Volume Today	40.08K
Avg Daily Volume (30D)	21.43K
Relative Volume	1.87x
Volatility (10D)	94.07
Volatility (30D)	76.14
Free Float	93.73%

Analyst Consensus

BUY

Current Price $1.19

Mean Target $17.00

52W Low$0.96 52W High$5.10

Current

Target

$0.96 $5.10

Current Analyst target

+1,328.57% upside potential · 5 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001S6FLZ2

ISINUS15117N7012

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -0.25% ARGX.BR argenx SE +0.82% ARGX argenx SE +2.34% 2269.HK WuXi Biologics (Cayman) Inc. -1.30% GMAB Genmab A/S +1.28%

Company Profile

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.